Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, day 56 33% Improvement Relative Risk Mortality, day 30 40% Hospitalization 20% c19early.org/e Abul et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 1,687 patients in the USA (December 2020 - September 2021) Lower mortality with aspirin (p=0.025) Abul et al., medRxiv, doi:10.1101/2022.08.03.22278392 Favors aspirin Favors control
Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes
Abul et al., medRxiv, doi:10.1101/2022.08.03.22278392 (Preprint)
Abul et al., Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes, medRxiv, doi:10.1101/2022.08.03.22278392 (Preprint)
Aug 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,687 nursing home residents in the USA, showing significantly lower risk of mortality with chronic low-dose aspirin use. Low dose 81mg aspirin users had treatment ≥10 of 14 days prior to the positive COVID date, control patients had no aspirin use in the prior 14 days.
risk of death, 33.0% lower, HR 0.67, p = 0.03, treatment 46 of 511 (9.0%), control 201 of 1,176 (17.1%), Cox proportional hazards, day 56.
risk of death, 40.0% lower, HR 0.60, p = 0.01, treatment 33 of 511 (6.5%), control 154 of 1,176 (13.1%), Cox proportional hazards, day 30.
risk of hospitalization, 20.0% lower, HR 0.80, p = 0.13, treatment 103 of 511 (20.2%), control 352 of 1,176 (29.9%), Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abul et al., 4 Aug 2022, retrospective, USA, preprint, mean age 72.3, 10 authors, study period 13 December, 2020 - 18 September, 2021.
Contact: yasin_abul@brown.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.08.03.22278392; this version posted August 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Association of mortality and aspirin use for COVID-19 residents at VA Community Living Center Nursing Homes Authors: Yasin Abul MD¹, ², ³ Frank Devone MS¹ Thomas A Bayer MD¹, ², ³ Christopher Halladay MS¹ Kevin McConeghy PharmD, MS¹, ² Nadia Mujahid MD² Mriganka Singh MD, MS¹, ² Ciera Leeder MD, MS² Stefan Gravenstein MD, MPH¹, ², ³ James L. Rudolph MD, MS¹, ², ³ Institutions: ¹Center of Innovation in Long Term Services and Supports, Providence VA Medical Center, Providence, RI ²Division of Geriatric and Palliative Medicine, Warren Alpert Medical School of Brown University, Providence, RI ³Brown University School of Public Health Center for Gerontology and Healthcare Research Running Title: Covid-19 mortality and Aspirin Corresponding author information: Yasin Abul MD, yasin_abul@brown.edu Address: Captain John H. Harwood Research Center at the VA Providence Health Care System, 373 Niagara St., Providence, RI 02907 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.08.03.22278392; this version posted August 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Grant support: This work was supported by the Center of Innovation in Long-Term Services and Supports for Vulnerable Veterans, VA Providence Health Care System, Providence, RI, and the Office of Academic Affiliations Fellowship Program Conflict of Interest (Declaration of commercial interest): None Disclosure: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government Keywords: COVID-19, aspirin, mortality Abstract Background/Objectives: Coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state and increased thrombotic risk in infected individuals. Several complex and varied coagulation abnormalities were proposed for this association 1 .Acetylsalicylic acid(ASA, aspirin) is known to have inflammatory, antithrombotic properties and its use was reported as having potency to reduce RNA synthesis and replication of some types of coronaviruses including human coronavirus-299E (CoV-229E) and Middle East Respiratory Syndrome (MERS)CoV 2,3. We hypothesized that chronic low dose aspirin use may decrease COVID-19 mortality relative to ASA non-users. Methods: This is a retrospective, observational cohort analysis of residents residing at Veterans Affairs Community Living Centers from December 13, 2020, to September 18, 2021, with a positive SARS-CoV-2 PCR test. Low dose aspirin users had low dose (81mg) therapy (10 of 14 days) prior to the positive COVID date and were compared to aspirin non-users (no ASA in prior 14 days). The primary outcome was mortality at 30 and 56 days post positive test and hospitalization. 2 medRxiv preprint doi: https://doi.org/10.1101/2022.08.03.22278392; this..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit